Latest revenue
$141.2M
as of 2026-03-31
Latest net income
$108.0K
as of 2026-03-31
Net margin
0.1%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Surgical & Medical Instruments & Apparatus (138 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ATRC is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.37B
- Enterprise value
- $1.29B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.79×
- Dividend yield
- 0.0%
- 52-wk high
- $43.18
- 52-wk low
- $25.37
- Beta
- —
- Shares out
- 50.6M
5-year trend
What this company does
ITEM 1. BUSINESS Overview We are a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib or AF), left atrial appendage (LAA) management and post-operative pain management. Afib is an irregular heartbeat, or arrhythmia, which affects over 59 million people worldwide and is a growing epidemic. It is the most common cardiac arrhythmia encountered in clinical practice and results in high utilization of healthcare services and significant cost burden. Patients often progress from being in Afib intermittently (paroxysmal) to being in Afib continuously (non-paroxysmal). The continuous Afib patient population includes early persistent Afib, which lasts seven days to…
AI summary unavailable — showing raw filing excerpt
Generated from ATRC's filing dated 2026-02-19
Key risks
Table of Contents ITEM 1A. RISK FACTORS The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding other statements in this report. The following information should be carefully considered in addition to the other information set forth in this report, including the Management’s Discussion and Analysis of Financial Condition and Results of Operations section and Consolidated Financial Statements and accompanying notes. If any of the risks or uncertainties described below actually occur or continue to occur, our business, reputation, financial condition, results of operations, future prospects and stock price could be…
AI summary unavailable — showing raw filing excerpt
Generated from ATRC's filing dated 2026-02-19
Profitability
Gross margin
75.0%
0.4%Operating margin
-1.8%
79.4%Net margin
-2.1%
77.7%Return on equity
-2.3%
76.0%Return on assets
-1.7%
76.1%Leverage
Debt / equity
0.33×
2.5%Long-term debt / equity
0.13×
6.3%Debt / assets
24.8%
1.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $141.2M | +14.3% | $108.0K | +101.6% | 0.1% |
Q4 2025 2025-12-31 | $140.5M | +13.1% | $1.8M | +111.3% | 1.2% |
Q3 2025 2025-09-30 | $134.3M | +15.8% | $-267.0K | +96.6% | -0.2% |
Q2 2025 2025-06-30 | $136.1M | +17.1% | $-6.2M | +22.7% | -4.5% |
Q1 2025 2025-03-31 | $123.6M | +13.6% | $-6.7M | +49.2% | -5.5% |
Q4 2024 2024-12-31 | $124.3M | — | $-15.6M | — | -12.5% |
Q3 2024 2024-09-30 | $115.9M | +17.9% | $-7.9M | +13.3% | -6.8% |
Q2 2024 2024-06-30 | $116.3M | +15.2% | $-8.0M | -56.5% | -6.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Surgical & Medical Instruments & Apparatus · SIC 3841
Your notes
Keep private notes on ATRC — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$1.7M
Net activity
−$1.7M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ATRC
Institutional value
$514.0M
Total shares held
19.3M
Distinct holders
123
-111 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 4.0M | $115.3M | -23.1K (-0.6%) | Trimmed |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.7M | $77.1M | — | New |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $61.5M | — | New |
| 4 | DIMENSIONAL FUND ADVISORS LP | 997.8K | $28.5M | +75.9K (+8.2%) | Added |
| 5 | Champlain Investment Partners, LLC | 971.1K | $27.7M | -202.5K (-17.3%) | Trimmed |
| 6 | KENNEDY CAPITAL MANAGEMENT LLC | 834.2K | $23.8M | -3.2K (-0.4%) | Trimmed |
| 7 | Voya Investment Management LLC | 719.6K | $20.5M | +7.3K (+1.0%) | Added |
| 8 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 555.1K | $15.8M | -14.6K (-2.6%) | Trimmed |
| 9 | WCM INVESTMENT MANAGEMENT, LLC | 359.8K | $10.2M | -12.9K (-3.5%) | Trimmed |
| 10 | Connor, Clark & Lunn Investment Management Ltd. | 345.4K | $9.9M | -33.1K (-8.7%) | Trimmed |
| 11 | VANGUARD FIDUCIARY TRUST CO | 342.9K | $9.8M | — | New |
| 12 | Nuveen, LLC | 336.7K | $9.6M | +468 (+0.1%) | Added |
| 13 | First Eagle Investment Management, LLC | 262.1K | $7.5M | +145.5K (+124.8%) | Added |
| 14 | SEI INVESTMENTS CO | 260.8K | $7.4M | +102.5K (+64.7%) | Added |
| 15 | WASATCH ADVISORS LP | 253.9K | $7.2M | -99.9K (-28.2%) | Trimmed |
| 16 | Universal- Beteiligungs- und Servicegesellschaft mbH | 215.5K | $6.1M | +22.3K (+11.5%) | Added |
| 17 | NICHOLAS COMPANY, INC. | 204.6K | $5.8M | -910 (-0.4%) | Trimmed |
| 18 | FIRST TRUST ADVISORS LP | 189.3K | $5.4M | +71.5K (+60.7%) | Added |
| 19 | Advisors Capital Management, LLC | 182.3K | $5.2M | -539 (-0.3%) | Trimmed |
| 20 | JPMORGAN CHASE & CO | 171.3K | $4.8M | -8.3K (-4.6%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ATRC's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.